Elastase activity on sputum neutrophils correlates with severity of lung disease in cystic fibrosis
- PMID: 29545279
- DOI: 10.1183/13993003.01910-2017
Elastase activity on sputum neutrophils correlates with severity of lung disease in cystic fibrosis
Abstract
Neutrophil elastase (NE) is a key risk factor for severity of cystic fibrosis (CF) lung disease. Recent studies identified increased NE activity on the surface of airway neutrophils from CF-like mice and patients with CF. However, the role of surface-bound NE in CF lung disease remains unknown. We determined the relationship between surface-bound NE activity and severity of lung disease in CF.Surface-bound NE activity was measured on sputum neutrophils from 35 CF patients and eight healthy controls using novel lipidated Förster resonance energy transfer reporters and correlated with free NE activity, neutrophil counts, interleukin-8, myeloperoxidase and antiproteases in sputum supernatant, and with lung function parameters.Surface-bound NE activity was increased in CF compared to healthy controls (p<0.01) and correlated with free NE activity (p<0.05) and other inflammation markers (p<0.001). Surface-bound and free NE activity correlated with forced expiratory volume in 1 s % predicted (p<0.01 and p<0.05), but only surface-bound NE activity correlated with plethysmographic functional residual capacity % pred (p<0.01) in patients with CF.We demonstrate that surface-bound NE activity on airway neutrophils correlates with severity of lung disease in patients with CF. Our results suggest that surface-bound NE activity may play an important role in the pathogenesis and serve as novel biomarker in CF lung disease.
Copyright ©ERS 2018.
Conflict of interest statement
Conflict of interest: A.S. Dittrich reports grants from the German Cystic Fibrosis Association Mukoviszidose e.V. (number 1605) and the Heidelberg Research Centre for Molecular Medicine Career Development Fellowship, during the conduct of the study. Conflict of interest: F. Herth has received grants, personal fees and non-financial support from Novartis, Chiesi, Boehringer, Astra, Uptake, Broncus, Pulmonx, Olympus, BTG and Ethicon, outside the submitted work. Conflict of interest: C. Schultz co-founded SiChem in 2001 and still own part of the company. SiChem is the sole producer of FRET probes used in this manuscript. Conflict of interest: M.A. Mall received grants from the German Federal Ministry of Education and Research (grant contract number 82DZL00401 and 82DZL004A1) and the European Commission (Seventh Framework Programme Project number 603038 CFMatters), during the conduct of the study; and personal fees for advisory board participation, consultancy, and lecture fees from Vertex, personal fees for advisory board participation and consultancy, from Spyrex, Polyphor and Boehringer Ingelheim, personal fees for advisory board participation from ProQR, PTC Pharmaceuticals, Arrowhead and Pro Axis, and lecture fees from Bayer, outside the submitted work. In addition, M.A. Mall has a patent on the Scnn1b-transgenic mouse with royalties paid, and a patent on use of sodium channel blockers for early therapy of obstructive lung diseases issued.
Similar articles
-
Sputum peroxidase activity correlates with the severity of lung disease in cystic fibrosis.Pediatr Pulmonol. 1995 Jan;19(1):1-9. doi: 10.1002/ppul.1950190102. Pediatr Pulmonol. 1995. PMID: 7675551
-
Lack of neutrophil elastase reduces inflammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fibrosis-like lung disease.Am J Respir Crit Care Med. 2014 May 1;189(9):1082-92. doi: 10.1164/rccm.201311-1932OC. Am J Respir Crit Care Med. 2014. PMID: 24678594
-
Neutrophil elastase correlates with increased sphingolipid content in cystic fibrosis sputum.Pediatr Pulmonol. 2018 Jul;53(7):872-880. doi: 10.1002/ppul.24001. Epub 2018 Apr 6. Pediatr Pulmonol. 2018. PMID: 29624923 Free PMC article.
-
Proteases and antiproteases in cystic fibrosis: pathogenetic considerations and therapeutic strategies.Respiration. 1995;62 Suppl 1:25-8. doi: 10.1159/000196490. Respiration. 1995. PMID: 7792437 Review.
-
Predicting disease progression in cystic fibrosis.Expert Rev Respir Med. 2018 Nov;12(11):905-917. doi: 10.1080/17476348.2018.1519400. Epub 2018 Sep 13. Expert Rev Respir Med. 2018. PMID: 30173593 Review.
Cited by
-
Inflammation-Associated Cytotoxic Agents in Tumorigenesis.Cancers (Basel). 2023 Dec 22;16(1):81. doi: 10.3390/cancers16010081. Cancers (Basel). 2023. PMID: 38201509 Free PMC article. Review.
-
Pulmonary exacerbations in early cystic fibrosis lung disease are marked by strong modulation of CD3 and PD-1 on luminal T cells.Front Immunol. 2023 Sep 21;14:1194253. doi: 10.3389/fimmu.2023.1194253. eCollection 2023. Front Immunol. 2023. PMID: 37809107 Free PMC article.
-
Mechanisms by which the cystic fibrosis transmembrane conductance regulator may influence SARS-CoV-2 infection and COVID-19 disease severity.FASEB J. 2023 Nov;37(11):e23220. doi: 10.1096/fj.202300077R. FASEB J. 2023. PMID: 37801035
-
The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species.Front Pharmacol. 2023 Jul 19;14:1208780. doi: 10.3389/fphar.2023.1208780. eCollection 2023. Front Pharmacol. 2023. PMID: 37538173 Free PMC article.
-
Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis: a multinational retrospective cohort study.Eur Respir J. 2023 Oct 26;62(4):2300174. doi: 10.1183/13993003.00174-2023. Print 2023 Oct. Eur Respir J. 2023. PMID: 37474158 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials